AbbVie Acquires Mavupharma for its STING (STimulator of INterferon Genes) Modulators to Treat Cancer

Shots:

• AbbVie has acquired Mavupharma to develop STING modulators and to advance Mavupharma’s lead candidate MAVU-104 towards clinical study
• The focus of the acquisition is to bolster AbbVie’s early-stage oncology portfolio with the addition of Mavupharma’s platform which involves the development of transformative therapies for cancer patients
• MAVU-104 is an orally administered ENPP1 inhibitor allowing highly controlled enhancement of STING signaling in tumors without the need for injections

Click here to read full press release/ article | Ref: AbbVie | Image: Mavupharma